InoCells offers stem cell therapy and banking services to hospitals and IVF centers, aimed at rejuvenating the ovaries of infertile patients with diminished egg quality and quantity. This therapy significantly increases the likelihood of these patients achieving pregnancy with their own biological children, providing a viable alternative to egg donation or adoption.
Funding
$50K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many women facing infertility, particularly those with diminished ovarian reserve or poor egg quality, have limited options for conceiving with their own eggs. These patients often face the difficult decision of pursuing egg donation or adoption.
Solution
InoCells offers a stem cell therapy and banking service designed to rejuvenate the ovaries of infertile patients, increasing their chances of conceiving with their own biological children. The company partners with hospitals and IVF centers to provide this therapy, which aims to improve egg quality and quantity. By utilizing stem cell technology, InoCells provides a potential alternative for patients who may have otherwise needed to consider egg donation or adoption to achieve pregnancy.
Target Audience
The primary customers are hospitals and IVF centers that treat infertile patients, specifically those with diminished ovarian reserve or poor egg quality.
Features
- Stem cell therapy to rejuvenate ovaries
- Banking services for stem cells
- Aims to improve egg quality and quantity
- Increases the likelihood of pregnancy using the patient's own eggs
- Services offered through partnerships with hospitals and IVF centers